Consider some of the most recent weight loss injection stats. It’s a market that’s growing quickly. Here’s what you need to know.
GLP-1s work. That’s easy to see. That’s why so many companies are pouring money into them. News broke that shows what’s happening.
Research shows the global market will hit $71b by 2032. Novo Nordisk will capture about half the market. That’s a value of $33B for the company. Eli Lilly will make up about 45% of the market as well.
Sales for Ozempic reached $3.2 billion in the second quarter. Wegovy sales hit $1.1 billion. Novo reported a 30% growth from 2022 for Ozempic. Eli Lilly’s Mounjaro hit $980 million in that time. That gives the company 28% of the market.
The GLP-1 receptor agonist market could reach $168B by 2033. That’s data from GlobalData surveys. It shows five drugs that will make this happen:
This report shows these 5 drugs will make up 83% of the market. The study feels Mounjaro will reach $33.4 billion in sales annually by 2029. That comes after the recent reports of Mounjaro reducing heart disease risk.
Another study reported by Markets And Markets shows more insight. It pins the current GLP-1 market at $47.4B in value in 2024. It expect it to reach $471.1 by 2032. That is on a global scale. It shows it would grow at a CAGR of 33.2%. That’s in just the span from 2024 to 2032.
This is up from another report from Grand View Research for 2023. That report from the market size was $36.79B in 2023. It expected it to grow at a rate of 21.65% from 2024 to 2030. Others estimate the GLP-1 market will reach $100b by 2030.
